

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | |
|------------------------|-------------------|
| Application Number | 10/520,207 |
| Filing Date | April 1, 2003 |
| First Named Inventor | Alan M. Fogelman |
| Group Art Unit | 1654 |
| Examiner Name | Jeffrey E. Russel |
| Attorney Docket Number | 407T-301110US |
| Date Submitted | October 10, 2005 |

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal |
|----------------------|-------------|----------------------|-------------------------|--|--|---|
| | | Number | Kind Code (if known) | | | |
| JER | 1 | 5,358,934 | | Borovsky et al | 10-1994 | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|----------------------|-------------|-------------------------|-------------|-------------------------|--|---|---|---|
| | | Office | Number | Kind Code (if known) | | | | |
| JER | 2 | WO | 91/05043 A1 | | Schering | 04-1991 | | |
| I | 3 | WO | 00/34469 A1 | | Research Foundation | 06-2000 | | |
| I | 4 | WO | 02/22161 A2 | | Universitair Medisch | 03-2002 | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|----------------------|-------------|---|---|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|------------------|--------------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|-----------------------|------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

| | |
|------------------------|----------------------------------|
| Application Number | 40/688,083 10/520,207 |
| Filing Date | October 6, 2003 |
| First Named Inventor | Dallas A. Rabenstein |
| Group Art Unit | 1653 |
| Examiner Name | Davenport, A. |
| Attorney Docket Number | 407T-891101US |
| Date Submitted | February 27, 2004 |

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT.

(use as many sheets as necessary)

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal |
|----------------------|-------------|----------------------|-------------------------|--|--|---|
| | | Number | Kind Code (if known) | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|----------------------|-------------|-------------------------|------------|-------------------------|--|--|---|---|
| | | Office | Number | Kind Code (if known) | | | | |
| JER | 1 | EP | 1186299 A1 | | | 13.02.2002 | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|----------------------|-------------|---|---|
| JER | 2 | PCT Search Report for PCT/US03/09988, mailed October 21, 2003. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|------------------|--------------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|-----------------------|------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

| | |
|------------------------|-----------------------|
| Application Number | 10/120,308 10/520,207 |
| Filing Date | April 5, 2002 |
| First Named Inventor | Alan M. Fogelman |
| Group Art Unit | 1654 |
| Examiner Name | Jeffrey E. Russel |
| Attorney Docket Number | 407T-301100US |
| Date Submitted | November 23, 2004 |

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

OCT 13 2002

(use as many sheets as necessary)

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal |
|-------------------|----------|----------------------|----------------------|---|---|---|
| | | Number | Kind Code (if known) | | | |
| JER | 1 | 5,733,879 | | Rosseneu et al. | 3/31/1998 | |
| | 2 | 6,004,925 | | Dasseux et al. | 12/21/1999 | |
| | 3 | 6,037,323 | | Dasseux et al. | 3/14/2000 | |
| | 4 | 6,046,166 | | Dasseux et al. | 4/4/2000 | |
| | 5 | 2001/0005714 A1 | | Boffelli et al. | 6/28/2001 | |
| | 6 | 6,265,377 | | Dasseux et al. | 7/24/2001 | |
| | 7 | 6,287,590 | | Dasseux et al. | 9/11/2001 | |
| | 8 | 6,329,341 | | Dasseux et al. | 12/11/2001 | |
| | 9 | 6,376,464 | | Dasseux et al. | 4/23/2002 | |
| | 10 | 6,455,088 | | Dasseux et al. | 9/24/2002 | |
| | 11 | 6,518,412 | | Dasseux et al. | 2/11/2003 | |
| | 12 | 6,573,239 | | Dasseux et al. | 6/3/2003 | |
| | 13 | 6,602,854 | | Dasseux et al. | 8/5/2003 | |
| | 14 | 2003/0045460 A1 | | Fogelman et al. | 3/6/2003 | |
| | 15 | 6,630,450 | | Dasseux et al. | 10/7/2003 | |
| | 16 | 6,716,816 | | Dasseux et al. | 4/6/2004 | |
| | 17 | 6,734,169 | | Dasseux et al. | 5/11/2004 | |
| | 18 | 6,753,313 | | Dasseux et al. | 6/22/2004 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|-------------------|----------|-------------------------|--------|----------------------|---|---|---|---|
| | | Office | Number | Kind Code (if known) | | | | |
| JER | 19 | IN | 185761 | | Council of Scientific and | 04/28/2004 04/28/2001 | | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


COPY FROM PARENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: left;">Complete if Known</th> </tr> <tr> <td style="width: 50%;">Application Number</td> <td>10/120,500 10/520,207</td> </tr> <tr> <td>Filing Date</td> <td>April 5, 2002</td> </tr> <tr> <td>First Named Inventor</td> <td>Alan M. Fogelman</td> </tr> <tr> <td>Group Art Unit</td> <td>1654</td> </tr> <tr> <td>Examiner Name</td> <td>Jeffrey E. Russel</td> </tr> <tr> <td>Attorney Docket Number</td> <td>407T-301100US</td> </tr> <tr> <td>Date Submitted</td> <td>November 23, 2004</td> </tr> </table> | Complete if Known | | Application Number | 10/120,500 10/520,207 | Filing Date | April 5, 2002 | First Named Inventor | Alan M. Fogelman | Group Art Unit | 1654 | Examiner Name | Jeffrey E. Russel | Attorney Docket Number | 407T-301100US | Date Submitted | November 23, 2004 |
|--|--|-------------------|--|--------------------|----------------------------------|-------------|---------------|----------------------|------------------|----------------|------|---------------|-------------------|------------------------|---------------|----------------|-------------------|
| Complete if Known | | | | | | | | | | | | | | | | | |
| Application Number | 10/120,500 10/520,207 | | | | | | | | | | | | | | | | |
| Filing Date | April 5, 2002 | | | | | | | | | | | | | | | | |
| First Named Inventor | Alan M. Fogelman | | | | | | | | | | | | | | | | |
| Group Art Unit | 1654 | | | | | | | | | | | | | | | | |
| Examiner Name | Jeffrey E. Russel | | | | | | | | | | | | | | | | |
| Attorney Docket Number | 407T-301100US | | | | | | | | | | | | | | | | |
| Date Submitted | November 23, 2004 | | | | | | | | | | | | | | | | |



| | | | | | | | |
|-----|----|----|----------|--|---------------------|--|--|
| | | | | | Industrial Research | | |
| JER | 20 | WO | 97/36927 | | Boffelli et al. | | |
| | | | | | | | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | | |
|---|----------|---|-----------------|------------|
| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T | |
| JER | 21 | Aravinda, S., Shamala, N., Das, C. , Sriranjini, A. , Karle, I. And Balaram, P. Aromatic-Aromatic Interactions in Crystal Structures of Helical Peptide Scaffolds Containing Projecting Phenylalanine Residues, J.Am Chem Soc. 2003; 125:5308-5315. | | |
| | 22 | Ashby D, Gamble J, Vadas M, Fidge N, Siggins S, Rye K, Barter PJ. Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression. <i>Atherosclerosis</i> . 2001;154:113-121. | | |
| | 23 | Ashby DT, Rye K-A, Clay MA., Vadas MA, Gamble J, Barter PJ. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> , 1998,18:1450-1455. | | |
| | 24 | Baker PW, Rye K-A, Gamble JR, Vadas MA, Barter PJ. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical cell endothelial cells. <i>Journal of Lipid Research</i> , 1999, 40:345-353. | | |
| | 25 | Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. <i>J Lipid Res</i> 2000;41:1261-1267. | | |
| | 26 | Barter PJ, Baker PW, Rye K-A.. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. <i>Current Opinion in Lipidology</i> , 2002, 13:285-288. | | |
| | 27 | Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease. <i>Atherosclerosis</i> , 1996, 121:1-12. | | |
| | 28 | Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J. | | |
| Examiner Signature | | /Jeffrey Russel/ | Date Considered | 03/13/2007 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PATENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

| | |
|------------------------|----------------------------------|
| Application Number | 10/120,508 10/520,207 |
| Filing Date | April 5, 2002 |
| First Named Inventor | Alan M. Fogelman |
| Group Art Unit | 1654 |
| Examiner Name | Jeffrey E. Russel |
| Attorney Docket Number | 407T-301100US |
| Date Submitted | November 23, 2004 |

(use as many sheets as necessary)

JER

Circulating cell adhesion molecules and death in patients with coronary artery disease. *Circulation* 2001;104:1336-1342.

29

Bourdillon MC, Poston RN, Covacho C, Chignier E, Bricca G, McGregor JL. ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE(-/-)/ICAM-1(-/-)) fed a fat or a chow diet. *Arterioscler Thromb Vasc Biol* 2000;20:2630-2635.

30

Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. *Proc Natl Acad Sci U S A*. 1992;89:10316-10320.

31

Burger D, Dayer J-M. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? *Autoimmunity Reviews* 2002;1:111-117.

32

Calabresi L, Franceschini G, Sirtori CR, De Palma A, Saresella M, Ferrante P, Taramelli D. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. *Biochem Biophys Res Commun*. 1997;238:61-65.

33

Calabresi L, Gomasaschi M, Villa B, Omoboni L, Dmitrieff C, Franceschini G. Elevated cellular adhesion molecules in subjects with low HDL-cholesterol. *Arterioscler Thromb Vasc Biol* 2002;22:656-661.

34

Carlos TM, Schwartz BR, Kovach NL, Yee E, Rosa M, Osborn L, Chi-Rosso G, Newman B, Lobb R, Rosso M, et al. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. *Blood* 1990;76:965-970.

35

Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species oxidation of LDL by myeloperoxidase and reactive nitrogen species. *Arterioscler Thromb Vasc Biol*. 2000;20:1716-1723.

36

Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. *JAMA* 1986;256:2835-2838.

37

Chiesa G, Monteggia E, Marchesi M, Lorenzon P, Laucello M, Lorusso V, Di Mario C, Karvouni E, Newton RS, Bisgaier CL, Franceschini G, Sirtori CR. Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. *Circ Res*. 2002;90:974-980.

Examiner
Signature

/Jeffrey Russel/

Date
Considered

03/13/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| | |
|------------------------|----------------------------------|
| Application Number | 10/120,508 10/520,207 |
| Filing Date | April 5, 2002 |
| First Named Inventor | Alan M. Fogelman |
| Group Art Unit | 1654 |
| Examiner Name | Jeffrey E. Russel |
| Attorney Docket Number | 407T-301100US |
| Date Submitted | November 23, 2004 |

| | | | |
|--------------------|------------------|---|----------------------------|
| JER | 38 | Christison J, Karjalainen A, Brauman J, Bygrave F, Stocker R. Rapid reduction and removal of HDL- but not LDL-associated cholesteryl ester hydroperoxides by rat liver perfused in situ. <i>Biochem J</i> . 1996;314:739-742. | |
| | 39 | Clay MA, Pyle DH, Rye K-A, Vadas MA, Gamble JR, Barter PJ. Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. <i>Atherosclerosis</i> , 2001;157:23-29.. | |
| | 40 | Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, Haskard DO. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. <i>rculation</i> 2001;103:108-112. | |
| | 41 | Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. <i>Arterioscler Thromb Vasc Biol</i> . 1995;15:1987-1994. | |
| | 42 | Cockerill GW, Saklatvala J, Ridley SH, Yarwood H, Miller NE, Oral B, Nithyanathan S, Taylor G, Haskard DO. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. <i>Arterioscler Thromb Vasc Biol</i> . 1999;19:910-917. | |
| | 43 | Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. <i>Journal of Clinical Investigation</i> 2001;107:1255-1262. | |
| | 44 | Cyrus T, Pratico D, Zhao L, Witztum JL, Rader DJ, Rokach J, FitzGerald GA, Funk CD. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice. <i>Circulation</i> . 2001;103:2277-2282. | |
| | 45 | Dansky HM, Barlow CB, Lominska C, Sikes JL, Kao C, Weinsaft J, Cybulsky MI, Smith JD. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. <i>Arterioscler Thromb Vasc Biol</i> 2001;21:1662-1667.. | |
| | 46 | Dansky HM, Charlton SA, Barlow CB, Tamminen M, Smith JD, Frank JS, Breslow JL. Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium. <i>J Clin Invest</i> . 1999;104:31-39 . | |
| | 47 | Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. <i>Am J Pathol</i> 2003;163:1117-1125. | |
| Examiner Signature | /Jeffrey Russel/ | | Date Considered 03/13/2007 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Patent and Trademark Office

PTO/SB/08A (04-03)


Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

| | |
|------------------------|----------------------------------|
| Application Number | 10/120,306 10/520,207 |
| Filing Date | April 5, 2002 |
| First Named Inventor | Alan M. Fogelman |
| Group Art Unit | 1654 |
| Examiner Name | Jeffrey E. Russel |
| Attorney Docket Number | 407T-301100US |
| Date Submitted | November 23, 2004 |



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| | | | |
|-----|----|---|--|
| JER | 48 | Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyriakopoulos A. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and Eselectin in human atherosclerosis. <i>J Pathol</i> 1993;171:223-229. | |
| | 49 | De Caterina R, Bernini W, Carluccio MA, Liao JK, Libby P. Structural requirements for inhibition of cytokine-induced endothelial activation by unsaturated fatty acids. <i>J. Lipid Res.</i> 1998;39:1062-1070. | |
| | 50 | Dimayuga P, Zhu J, Oguchi S, Chyu KY, Xu XO, Yano J, Shah PK, Nilsson J, Cercek B. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periaortic cuff-induced carotid injury in apoE null mice. <i>Biochem Biophys Res Commun.</i> 1999;264:465-468. | |
| | 51 | Epand RM, Stafford A, Leon B, Lock PE, Tytler EM, Segrest JP, Anantharamaiah GM. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. <i>Arterioscler. Thromb.</i> 1994;14:1775-1783. | |
| | 52 | Fleisher LN, Tall AR, Witte LD, Miller RW, Cannon PJ. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. <i>J. Biol. Chem.</i> 1982;257:6653-6655. | |
| | 53 | Fogelman AM, Shechter I, Seager J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. <i>Proc Natl Acad Sci U S A.</i> 1980;77:2214-2218. | |
| | 54 | Fogelman AM. When good cholesterol goes bad. <i>Nat Med</i> 2004;10:902-903. | |
| | 55 | Forte TM, Subbanagounder G, Berliner JA, Blanche PJ, Clermont AO, Jia Z, Oda MN, Krauss RM, Bielicki JK. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. <i>J. Lipid Res.</i> 2002;43:477-485. | |
| | 56 | Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. <i>N. Engl. J. Med.</i> 1999; 340: 448-454. | |
| | 57 | Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. <i>J Biol Chem</i> 1998;273:6088-6095. | |
| | 58 | Garner B, Witting PK, Waldeck AR, Christison JK, Raftery M, Stocker R. Oxidation | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CONFIDENTIAL

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| | |
|------------------------|----------------------------------|
| Application Number | 10/420,500 10/520,207 |
| Filing Date | April 5, 2002 |
| First Named Inventor | Alan M. Fogelman |
| Group Art Unit | 1654 |
| Examiner Name | Jeffrey E. Russel |
| Attorney Docket Number | 407T-301100US |
| Date Submitted | November 23, 2004 |



| | | | |
|-----|----|---|--|
| JER | | of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. <i>J Biol Chem</i> 1998;273:6080-6087. | |
| | 59 | Gaut JP, Byun J, Tran HD, Lauber WM, Carroll JA, Hotchkiss RS, Belaaouaj A, Heinecke JW. Myeloperoxidase produces nitrating oxidants in vivo. <i>J Clin Invest</i> 2002;109:1311-1319. | |
| | 60 | George J, Afek A, Shaish A, Levkovitz H, Bloom N, Cyrus T, Zhao L, Funk CD, Sigal E, Harats D. 12/15-lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. <i>Circulation</i> . 2001;104:1646- 1650. | |
| | 61 | Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. <i>Am. J. Med.</i> 1977;62: 707-714. | |
| | 62 | Harats D, Shaish A, George J, Mulkins M, Kurihara H, Levkovitz H, Sigal E. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. <i>Arterioscler Thromb Vasc Biol</i> . 2000;20:2100-2105. | |
| | 63 | Henricksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptor for acetylated low density lipoproteins. <i>Proc Natl Acad Sci U S A</i> . 1981;78:6499-6503. | |
| | 64 | Hessler JR, Robertson AL, Chisolm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. <i>Atherosclerosis</i> 1979; 32:213-229. | |
| | 65 | Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The atherosclerosis risk in communities (ARIC) study. <i>Circulation</i> 1997;96:4219- 4225. | |
| | 66 | Jin W, Millar JS, Broedl U, et al. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. <i>J Clin Invest</i> 2003;111:357-362. | |
| | 67 | Karle, I., Gopi, H., and Balaram, P. Crystal structure of hydrophobic 19-residue peptide helix containing three centrally located D amino acids PNAS 2003;100:24:13946-13951 | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PAPER

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| | |
|------------------------|----------------------------------|
| Application Number | 10/126,508 10/520,207 |
| Filing Date | April 5, 2002 |
| First Named Inventor | Alan M. Fogelman |
| Group Art Unit | 1654 |
| Examiner Name | Jeffrey E. Russel |
| Attorney Docket Number | 407T-301100US |
| Date Submitted | November 23, 2004 |



| | | | |
|-----|----|--|--|
| JER | 68 | Karle, I, Prasad, S. and Balaram, P. A combined extented and helical backbone for Boc-(Ala-Leu-Ac7C)2-OME, Peptides Res. 2004; 63:174-180 | |
| | 69 | Ko Y, Haring R, Stiebler H, Wieczorek AJ, Vetter H, Sachinidis A. Highdensity lipoprotein reduces epidermal growth factor-induced DNA synthesis in vascular smooth muscle cells. <i>Atherosclerosis</i> 1993;99: 253-259. | |
| | 70 | Kume N, Cybulsky MI, Gimbrone Jr MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. <i>Journal of Clinical Investigation</i> 1992;90:1138-1144. | |
| | 71 | Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. <i>Cell</i> 1991;65:859-873. | |
| | 72 | Lee SH, Oe T, Blair IA. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. <i>Science</i> 2001;292:2083-2086. | |
| | 73 | Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. <i>Proc. Natl. Acad. Sci. USA</i> 1993;90 : 12040-12044. | |
| | 74 | Li H, Cybulsky MI, Gimbrone MA, Jr., Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. <i>Arteriosclerosis and Thrombosis</i> 1993;13:197-204. | |
| | 75 | Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. <i>Circulation</i> 2002;105:1135-1143. | |
| | 76 | Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ, Shih W. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. <i>Circ Res.</i> 2002;91:120- 126. | |
| | 77 | Murugesan G, Sa G, Fox PL. High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor. <i>Circ. Res.</i> 1994;74 : 1149-1156. | |
| | 78 | Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of apoA-I/phosphosphatidycholine discs on plasma lipoproteins in humans.. <i>Arterioscler Thromb Vasc Biol.</i> 1999;19:979-989. | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CONFIDENTIAL


PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | |
|------------------------|----------------------------------|
| Application Number | 10/120,598 10/520,207 |
| Filing Date | April 5, 2002 |
| First Named Inventor | Alan M. Fogelman |
| Group Art Unit | 1654 |
| Examiner Name | Jeffrey E. Russel |
| Attorney Docket Number | 407T-301100US |
| Date Submitted | November 23, 2004 |

| | | |
|-----|----|--|
| JER | 79 | Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous apoA-I/lecithin discs increase pre-b-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. <i>J Lipid Res</i> 2001;42:1586-1593. |
| | 80 | Navab M, Anantharamaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. <i>J. Lipid Res.</i> 2004; 45: 993-1007. |
| | 81 | Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre- <input type="checkbox"/> high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apoE-null mice. <i>Circulation</i> 2004;109:r120-r125. |
| | 82 | Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. <i>Arterioscler Thromb Vasc Biol</i> 2001;21:481-488. |
| | 83 | Navab M, Hama S, Hough G et al. Oral synthetic phospholipids (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice. <i>Circulation</i> 2003;108:1735-1739. |
| | 84 | Navab M, Hama SY, Hough GP, et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. <i>J Lipid Res</i> 2001;42:1308-1317. |
| | 85 | Navab M, Hama-Levy, S, Van Lenten BJ, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraonase ratio. <i>J. Clin. Invest.</i> 1997; 99: 2005-2019. |
| | 86 | Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H., et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. <i>Journal of Clinical Investigation</i> 1991;88:2039-2046. |
| | 87 | Nievelstein PF, Fogelman AM, Mottino G, Frank JS. Lipid accumulation in rabbit aortic intima two hours after bolus infusion of low density lipoprotein: A deep-etch and immuno-localization study of ultra-rapidly frozen tissue. <i>Arteriosclerosis and Thrombosis</i> 1991;11:1795-1805. |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY FROM PAPER

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


Complete if Known

| | |
|------------------------|----------------------------------|
| Application Number | 10/120,500 10/520,207 |
| Filing Date | April 5, 2002 |
| First Named Inventor | Alan M. Fogelman |
| Group Art Unit | 1654 |
| Examiner Name | Jeffrey E. Russel |
| Attorney Docket Number | 407T-301100US |
| Date Submitted | November 23, 2004 |

| | | | |
|-----|----|---|--|
| JER | 88 | Lumsden AB, Chen C, Hughes JD, Kelly AB, Hanson SR, Harker LA. Anti- VLA-4 antibody reduces intimal hyperplasia in the endarterectomized carotid artery in nonhuman primates. <i>J Vasc Surg</i> 1997;26:87-93. | |
| | 89 | Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. <i>Nature</i> 1998;394:200- 203. | |
| | 90 | O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. <i>Circulation</i> 1996;93:672-82. | |
| | 91 | O'Connell BJ, Genest J Jr. High-density lipoproteins and endothelial function. <i>Circulation</i> 2001;104:1978-1983. | |
| | 92 | Oguchi S, Dimayuga P, Zhu J, Chyu KY, Yano J, Shah PK, Nilsson J, Cercek B. Monoclonal antibody against vascular cell adhesion molecule-1 inhibits neointimal formation after periadventitial carotid artery injury in genetically hypercholesterolemic mice. <i>Arterioscler Thromb Vasc Biol</i> 2000;20:1729-1736. | |
| | 93 | Papo N, Oren Z, Pag U, et al. The consequence of sequence alteration of an amphipathic α -helical antimicrobial peptide and its diastereomers. <i>J. Biol. Chem.</i> 2002;277(37): 33913-33921. | |
| | 94 | Parthasarathy S, Santanam N. Mechanisms of oxidation antioxidants, and atherosclerosis. <i>Curr Opin Lipidol</i> 1994;5:371-375. | |
| | 95 | Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of Creactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. <i>Circulation.</i> 2001;103:2531-2534. | |
| | 96 | Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. <i>Circulation.</i> 2000;102:2165-2168. | |
| | 97 | Ou J, Geiger T, Zhijun O, et al. AP-4F, antennapedia peptide linked to an amphipathic α helical peptide, increases the efficiency of lipofectamine-mediated gene transfection in endothelial cells. <i>Biochem Biophys Res Commun</i> 2003;305:605-610. | |
| | 98 | Ou J, Ou Z, Jones DW, et al. L-4F, an apolipoprotein A-I mimetic, dramatically improves vasodilation in hypercholesterolemic and sickle cell disease. <i>Circulation</i> 2003;107:2337-2341. | |

| | | | |
|-----------------------|------------------|--------------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|-----------------------|------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



ORIGINAL PAPER

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|----------------------------------|
| Application Number | 10/420,508 10/520,207 |
| Filing Date | April 5, 2002 |
| First Named Inventor | Alan M. Fogelman |
| Group Art Unit | 1654 |
| Examiner Name | Jeffrey E. Russel |
| Attorney Docket Number | 407T-301100US |
| Date Submitted | November 23, 2004 |

| | | | |
|-----|-----|---|--|
| JER | 99 | Ou Z, Ou J, Ackerman AW et al. L-4F, an apolipoprotein A-I mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. <i>Circulation</i> 2003;107:1520-1524. | |
| | 100 | Ranganathan, D, Kurur, S, Kunwar, A, Sarma, A, Vairamani, M, Karle, I. Channel-forming, self-assembling, bishelical amphiphilic peptides: design, synthesis and crystal structure of Py(Aibn) ₂₁ n=2, 3, 4. <i>J. Peptide Res.</i> 2000 56:416-426 | |
| | 101 | Reape TJ, Groot PH. Chemokines and atherosclerosis. <i>Atherosclerosis</i> 1999;147:213-225. | |
| | 102 | Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM. Human paraoxonase-3 is an HDL associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. <i>Arterioscler Thromb Vasc Biol</i> 2001;21:542- 547. | |
| | 103 | Reddy ST, Nguyen JT, Grijalva V, et al. Potential role for mitogen-activated protein kinase phosphatase-1 in the development of atherosclerotic lesions in mouse models. <i>Arterioscler Thromb Vasc Biol</i> 2004;24:1676-1681. | |
| | 104 | Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. <i>Circulation</i> 2002;105:2-4. | |
| | 105 | Rong JX, Li J, Reis ED, Choudhury RP, Dansky HM, Elmalem VI, Fallon JT, Breslow JL, Fisher EA. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. <i>Circulation</i> 2001;104:2447-2452. | |
| | 106 | Sattler W, Stocker R. Greater selective uptake by Hep G2 cells of highdensity lipoprotein cholesteryl ester hydroperoxides than of unoxidized cholesteryl esters. <i>Biochem J.</i> 1993;294:771-778. | |
| | 107 | Shah PK, Nilsson J, Kaul S. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. <i>Circulation</i> , 1998;97(8): 780-785. | |
| | 108 | Shah PK, Yano J, Reyes O, Chyu KY, Kaul S, Bisgaier CL, Drake S, Cercek B. High-dose recombinant apolipoproteins A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein Edeficient mice: | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CONFIDENTIAL

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT


(Use as many sheets as necessary)

| | |
|------------------------|----------------------------------|
| Application Number | 10/420,500 10/520,207 |
| Filing Date | April 5, 2002 |
| First Named Inventor | Alan M. Fogelman |
| Group Art Unit | 1654 |
| Examiner Name | Jeffrey E. Russel |
| Attorney Docket Number | 407T-301100US |
| Date Submitted | November 23, 2004 |

| | | | |
|-----|-----|---|--|
| JER | | potential implications for acute plaque stabilization. <i>Circulation</i> . 2001;103:3047-3050. | |
| | 109 | Shih D.M., Xia Y-R., Wang X-P., Miller E., Castellani L.W., Subbanagounder G., Cheroutre H., Faull K., Berliner J.A., Witztum J.L., Lusis A.J. Combined serum paraoxonase/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. <i>J. Biol. Chem.</i> , 2000;275:17527-17535. | |
| | 110 | Shih PT, Elices MJ, Fang ZT, Ugarova TP, Strahl D, Territo MC, Frank JS, Kovach NL, Cabanas C, Berliner JA, Vora DK. Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating beta integrin. <i>J Clin Invest</i> 1999;103:613-625. | |
| | 111 | Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF Jr, Penn MS, Sprecher DL, Vita JA, Hazen SL. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. <i>JAMA</i> 2003;289:1675-1680. | |
| | 112 | Singh IP, Baron S. Innate defences against viremia. <i>Rev Med Virol</i> 2000;10:395-403. | |
| | 113 | Sorescu D, Szocs K, Griendling KK. NAD(P)H oxidases and their relevance to atherosclerosis. <i>Trends Cardiovas Med</i> 2001;11:124-131. | |
| | 114 | Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Luscher TF, Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. <i>Circulation</i> . 2002;105:1399-1402. | |
| | 115 | Springer TA. Adhesion receptors of the immune system. <i>Nature</i> 1990;346:425-434. | |
| | 116 | Stannard AK, Khan S, Graham A, Owen JS, Allen SP. Inability of plasma high-density lipoproteins to inhibit cell adhesion molecule expression in human coronary artery endothelial cells. <i>Atherosclerosis</i> 2001;154:31-38. | |
| | 117 | Sugatani J, Miwa M, Komiyama Y, Ito S. High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. <i>J. Lipid Mediators Cell Signal</i> . 1996;13:73-88. | |
| | 118 | Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. <i>Circulation</i> 2002;106:484-490. | |
| | 119 | Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PROBATION

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|----------------------------------|
| Application Number | 10/120,506 10/520,207 |
| Filing Date | April 5, 2002 |
| First Named Inventor | Alan M. Fogelman |
| Group Art Unit | 1654 |
| Examiner Name | Jeffrey E. Russel |
| Attorney Docket Number | 407T-301100US |
| Date Submitted | November 23, 2004 |

| JER | | |
|--------------------|------------------|--|
| | | Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes proinflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. <i>J Clin Invest</i> 1995;96:2758- 2767. |
| | 120 | Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. <i>Circulation</i> 2001;103:2283-2288. |
| | 121 | Van Lenten BJ, Wagner AC, Anantharamaiah GM, Garber DW, Fishbein MC, Adhikary L, Nayak DP, Hama S, Navab M, Fogelman AM. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. <i>Circulation</i> 2002; 106:1127-1132. |
| | 122 | Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. <i>Circulation</i> . 2002;106:1439-1441. |
| | 123 | Walpole PL, Gotlieb AI, Cybulsky MI, Langille BL. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. <i>Arterioscler Thromb Vasc Biol</i> 1995;15:2-10. |
| | 124 | Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, Du BN, Fogelman AM, Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized-low density lipoprotein. <i>J Clin Invest</i> 1995;95:774-782. |
| | 125 | Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. <i>J Clin Invest</i> 1995;96:2882-2891. |
| | 126 | Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. <i>J Biol Chem</i> . 1999;274:33143-33147. |
| | 127 | Yamashita S, Maruyama T, Hirano K, et al. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. <i>Atherosclerosis</i> 2000;152:271-285. |
| | 128 | Yan D, Navab M, Bruce C et al. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. <i>J Lipid Res</i> 2004;45:1852-1858. |
| Examiner Signature | /Jeffrey Russel/ | Date Considered 03/13/2007 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY TO THE PATENT OFFICE

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | |
|---|------------------------|----------------------------------|
| Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT OCT 13 2005 (use as many sheets as necessary) | Complete if Known | |
| | Application Number | 10/120,508 10/520,207 |
| | Filing Date | April 5, 2002 |
| | First Named Inventor | Alan M. Fogelman |
| | Group Art Unit | 1654 |
| | Examiner Name | Jeffrey E. Russel |
| | Attorney Docket Number | 407T-301100US |
| Date Submitted | November 23, 2004 | |

| | | |
|-----|-----|---|
| JER | 129 | Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. <i>J. Clin. Invest.</i> 1988;82: 803-807. |
| | 130 | Zeihner AM, Schachinger V. Hohnloser SH, et al. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. <i>Circulation</i> 1994;89:2525-2532. |
| | 131 | Zhang R, Brennan ML, Shen Z, MacPherson JC, Schmitt D, Molenda CE, Hazen SL. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. <i>J Biol Chem</i> 2002;277:46116-46122. |
| | 132 | Zhang WJ, Stocker R, McCall MR, Forte TM, Frei B. Lack of inhibitory effect of HDL on TNFalpha-induced adhesion molecule expression in human aortic endothelial cells. <i>Atherosclerosis</i> 2002;165:241-249. |
| | 133 | Zhao L, Cuff CA, Moss e, Wille U, Cyrus T, Klein EA, Pratico D, Rader DJ, Hunter CA, Pure E, Funk CD. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. <i>J Biol Chem</i> 2002;277:35350-35356. |
| | 134 | Anantharamaiah et al. (1993) Pp. 109 In: The Amphipathic Helix, (Ed R.M. Epand. CRC press, Ann Arbor Mi) |
| | 135 | Bailey et al. (2001) Biochemistry; 40: 11828-11840 |
| | 136 | Clerio et al. (1999) Biochem J; 344: 375-383 |
| | 137 | Dota et al. (1999) Exp Eye Res; 69: 705-708 |
| | 138 | Fleming et al. (1999) J Molecular Endocrinology; 23:199-208 |
| | 139 | Gelissen et al. (1998) Biochem J; 331: 231-237 |
| | 140 | Griswold (1987) Biochemistry; 26:3297-3303 |
| | 141 | Hammad et al. (1997) J Biol Chem; 272: 18644-18649 |
| | 142 | Han et al. (2001) Nature Medicine; 7 338-343 |
| | 143 | Hasan et al. (2000) Hum Pathol; 31: 691-697 |
| | 144 | Hochgrebe et al. (1999) Experimental Cell Research; 249: 13-21 |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


COPY FOR PAPER

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|--|---------------------------------|-----------------------|-------------------|--|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary) | Substitute for form 1449A-B/PTO | | Complete if Known | |
| | Application Number | 10/120,500 | 10/520,207 | |
| | Filing Date | April 5, 2002 | | |
| | First Named Inventor | Alan M. Fogelman | | |
| | Group Art Unit | 1654 | | |
| | Examiner Name | Jeffrey E. Russel | | |
| | Attorney Docket Number | 407T-301100US | | |
| | Date Submitted | November 23, 2004 | | |

| | | | |
|-----|-----|---|--|
| JER | 145 | Hough <i>et al.</i> (200 [*]) Cancer Res; 61: 3869-3876 | |
| | 146 | Ishikawa <i>et al.</i> (1998) Arterioscler Thromb Vasc Biol; 18: 665-672 | |
| | 147 | Ishikawa <i>et al.</i> (2001) Atherosclerosis; 158: 215-225 | |
| | 148 | Jenne <i>et al.</i> (1989) <i>Proc Natl Acad Sci USA.</i> ; 86: 7123-7127 | |
| | 149 | Khan <i>et al.</i> (2000) Pathology; 258-261 | |
| | 150 | Kissinger <i>et al.</i> (1982) Biol Reprod 1982; 27:233-240 | |
| | 151 | Landes (1995) Pp. 1-12 In: Clusterin: Role in Vertebrate Development, Function, and Adaptation (Harmony JAK Ed.) pp 1-12, R.G. | |
| | 152 | Macknes <i>et al.</i> (1997) Arterioscler Thromb Vasc Biol; 17: 1233-1238 | |
| | 153 | McLaughlin <i>et al.</i> (2000) J Clin Invest; 106:1105-1113 | |
| | 154 | Mitsuhashi <i>et al.</i> (1997) J Clin Invest; 100: 847-854 | |
| | 155 | Morrissey <i>et al.</i> (2001) J Biochem Biophys Methods;48: 13-21 | |
| | 156 | Navab <i>et al.</i> (1997) J Clin Invest; 99:2005-2019 | |
| | 157 | Navab <i>et al.</i> (2000) J Lipid Res; 41:1495-1508 | |
| | 158 | Navab <i>et al.</i> (2000) J Lipid Research;41:1481-1494 | |
| | 159 | Navab <i>et al.</i> (2001) Arterioscler Thromb Vasc Biol. 2001;21:481-488 | |
| | 160 | Navab <i>et al.</i> (2001) Arterioscler Thromb Vasc Biol; 21:1451-1457 | |
| | 161 | Navab <i>et al.</i> (2002) Circulation; 105:290-292 | |
| | 162 | Newkirk <i>et al.</i> (1999) J Rheumatol; 26: 597-603 | |
| | 163 | Nishida <i>et al.</i> (1999) <i>Br J Ophthalmol</i> ; 83: 1178-1182) | |
| | 164 | Redondo <i>et al.</i> (2000) Am J Pathol; 157:393-399 | |
| | 165 | Segrest <i>et al.</i> (1990). Proteins:Structure, Function and Genetics; 8:103-117 Erratum (1991) Proteins:Structure, Function and Genetics 1991; 9:79 | |
| | 166 | Silkensen <i>et al.</i> (1999) Pept Res; 54: 449-457 | |
| | 167 | Steinberget <i>et al.</i> (1997) Clin Cancer Res;3: 1707-1711 | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY FOR PATENT

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|----------------------------------|
| Application Number | 10/120,508 10/520,207 |
| Filing Date | April 5, 2002 |
| First Named Inventor | Alan M. Fogelman |
| Group Art Unit | 1654 |
| Examiner Name | Jeffrey E. Russel |
| Attorney Docket Number | 407T-301100US |
| Date Submitted | November 23, 2004 |

| | | | |
|-----|-----|--|--|
| JER | 168 | Van Lenten <i>et al.</i> (2001) Circulation;103: 2283-2288 | |
| | 169 | Van Lenten <i>et al.</i> (2001) J Biol Chem;276: 1923-1929 | |
| | 170 | Wehrli <i>et al.</i> (2001) Nature Medicine; 7: 977-978 | |
| | 171 | Wellman <i>et al.</i> (2000) Blood; 96: 398-404 | |
| | 172 | Wong <i>et al.</i> (2000) Vision; 6: 184-191 | |
| | 173 | Xu <i>et al.</i> (2000) J Biol Chem; 275: 31770-3177 | |
| | | | |

| | | | |
|-----------------------|------------------|--------------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|-----------------------|------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PATENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

| | | |
|---|---|--|
| Substitute for form 1449A-B/PT INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Complete if Known Application Number 10/120,500 10/520,207 Filing Date April 5, 2002 First Named Inventor Alan M. Fogelman Group Art Unit 1654 Examiner Name Jeffrey E. Russel Attorney Docket Number 407T-301100US Date Submitted November 26, 2003 | |
|---|---|--|

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-------------|----------------------|-------------------------|--|--|---|
| Examiner Initials | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal |
| | | Number | Kind Code (if known) | | | |
| JER | 01 | 3,767,040 | | Tushaus | 10-23-1973 | |
| | 02 | 4,155,913 | | Hellerbach et al. | 05-22-1979 | |
| | 03 | 4,643,988 | | Segrest et al. | 02-17-1987 | |
| | 04 | 5,721,138 | | Lawn | 02-24-1998 | |
| | 05 | 5,733,549 | | Yamada et al. | 03-31-1998 | |
| | 06 | 5,814,467 | | Curtiss et al. | 09-29-1998 | |
| | 07 | 5,854,238 | | Kempen | 12-29-1998 | |
| | 08 | 6,037,323 | | Dasseux et al. | 03-14-2000 | |
| | 09 | 6,086,918 | | Stern et al. | 07-11-2000 | |

| Examiner Initials | | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|----------------------|----|-------------------------|----------|-------------------------|--|--|---|---|
| | | Office | Number | Kind Code (if known) | | | | |
| JER | 10 | WO | 97/36927 | A1 | Boffelli et al. | 10-09-1997 | | |
| | 11 | WO | 99/47566 | A1 | The UAB Research Foundation | 09-23-1999 | | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | | |
|---|----------|---|---|--|
| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T | |
| JER | 12 | ANANTHARAMAIAH (1986) "Synthetic Peptide Analogs of Appolipoproteins." <i>Methods in Enzymology</i> 128:627-647 | | |
| | 13 | ANANTHARAMAIAH and GARBER (1996) "Chromatographic Methods for Quantitation of Apolipoprotein A-I." <i>Meth. Enzymol.</i> 263: 267-282 | | |
| | 14 | ANANTHARAMAIAH et al. (1985) "Studies of Synthetic Peptide of the Amphipathic Helix." <i>The Journal of Biological Chemistry</i> 260:10248-10255 | | |
| | 15 | ANANTHARAMAIAH et al. (1990) "Use of Synthetic Peptide Analogues to Localize Lecithin: Cholseterol Acyltransferase Activating Domain in Apolipoprotein A-I." <i>Arteriosclerosis</i> 10:95-105 | | |


| | | | |
|-----------------------|------------------|--------------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|-----------------------|------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CONFIDENTIAL

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

| | | |
|--|--------------------------|----------------------------------|
| Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Complete if Known | |
| | Application Number | 10/120,308 10/520,207 |
| | Filing Date | April 5, 2002 |
| | First Named Inventor | Alan M. Fogelman |
| | Group Art Unit | 1654 |
| | Examiner Name | Jeffrey E. Russel |
| | Attorney Docket Number | 407T-301100US |
| | Date Submitted | November 26, 2003 |




| | | | |
|-----|----|--|--|
| JER | 16 | ANANTHARAMAIAH et al. (1993) "An Atlas of the Amphipathic Helical Domains of Human Exchangeable Plasma Apolipoproteins." Chapter. 6:109-142 In: <i>The Amphipathic Helix</i> (Epand, R. M., ed), CRC Press, Boca Raton, FL | |
| | 17 | ARMSTRONG et al. (1993) D amino acid levels in human physiological fluids, <i>Chirality</i> , 5: 375-378 | |
| | 18 | ATLAS-WHITE et al. (2000) "Localisation of clusterin in normal human sperm by immunogold electron microscopy." <i>Pathology</i> ; 258-261 | |
| | 19 | BADIMON et al. (1990) "Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-fed Rabbit." <i>J. Clinical Investigation</i> 85:1234-1241 | |
| | 20 | BAILEY et al. (2001) "Clusterin, a binding protein with a molten globule-like region." <i>Biochemistry</i> ; 40: 11828-11840 | |
| | 21 | BAUER et al. (1982) "SMS 201-995: A Very Potent and Selective Octapeptide Analogue of Somatostatin with Prolonged Action" <i>Life Sciences</i> 31:1133-1140. | |
| | 22 | BOFFELLI et al. (1997) "Reconstitution and Further Characterization of the Cholesterol Transport Activity of the Small-Intestinal Brush Border Membrane" <i>Biochemistry</i> 36:10784-10792. | |
| | 23 | BOFFELLI et al. (1997) "The uptake of cholesterol at the small-intestinal brush border membrane is inhibited by apolipoproteins." <i>FEBS Letters</i> , 411: 7-11 | |
| | 24 | BORHANI et al. (1999) "Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation." <i>Proc. Natl. Acad. Sci. USA</i> . 94:12291-12296 | |
| | 25 | BROUILLETTE and ANANTHARAMAIAH (1995) "Structural models of human apolipoprotein A-I." <i>Biochim. Biophys. Acta</i> 1256: 103-129 | |
| | 26 | BROUILLETTE et al. (2001) "Structural Models of Human Apolipoprotein A-I: A Critical Analysis and Review" <i>Biochimica et Biophysica Acta</i> 1531:4-46. | |
| | 27 | CALERO et al. (1999) "Functional and structural properties of lipid-associated apolipoprotein J (clusterin)." <i>Biochem J</i> ; 344: 375-383 | |
| | 28 | Canadian Pharmacists Association, Starlix General Monograph. http://cpha.infinetcomm.com/content/hcp/tools/cps_cnp_updates/starlix.cfm (12-10-2002) | |
| | 29 | CHUNG et al. (1985) "Studies of Synthetic Peptide Analogs of the Amphipathic Helix." <i>J. Biol. Chem.</i> 60(18): 10256-10262 | |
| | 30 | DATTA et al. (2001) "Effects of Increasing Hydrophobicity on the Physical-Chemical and Biological Properties of a Class A Amphipathic Helical Peptide." <i>J Lipid Research</i> 42:1096-1104. | |
| | 31 | DAVIDSON et al. (1994) "The Influence of Apolipoprotein Structure on the Efflux of Cellular Free Cholesterol to High Density Lipoprotein." <i>J. Biol. Chem.</i> 269(37): 22975-22982 | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|--|------------------------|----------------------------------|
| Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Complete if Known | |
| | Application Number | 10/420,508 10/520,207 |
| | Filing Date | April 5, 2002 |
| | First Named Inventor | Alan M. Fogelman |
| | Group Art Unit | 1654 |
| | Examiner Name | Jeffrey E. Russel |
| | Attorney Docket Number | 407T-301100US |
| | Date Submitted | November 26, 2003 |



| | | | |
|-----|----|---|--|
| JER | 32 | DIEDERICH et al. (2001) "Apolipoprotein AI and HDL ₃ Inhibit Spreading of Primary Human Monocytes through a Mechanism that Involves Cholesterol Depletion and Regulation of CD42." <i>Atherosclerosis</i> 159:313-324. | |
| | 33 | DOOLEY et al. (1994) "An All D-Amino Acid Opioid Peptide with Central Analgesic Activity from a Combinatorial Library" <i>Science</i> 2019-2022. | |
| | 34 | DOTA et al. (1999) "Clusterin in human corneal endothelium and aqueous humor." <i>Exp Eye Res</i> ; 69: 705-708 | |
| | 35 | DUNLOP and NEIDLE (1997) "The Orgion and Turnover of D-Serine in Brain." <i>Biochemical and Biophysical Research Communication</i> 235:26-30 | |
| | 36 | EHARA et al. (2001) "Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes." <i>Circulation</i> 103:1955-1960 | |
| | 37 | EPAND et al. (1987) "Studies Synthetic Peptide Analog of the Amphipathic Helix" <i>J. Biol. Chem.</i> 262(19): 9389-9396 | |
| | 38 | FIELD et al. (2001) "Gene expression of sterol regulatory element-binding proteins in hamster small intestine." <i>Journal of Lipid Research</i> 42:1-9 | |
| | 39 | FIELDING and FIELDING (1995) "Molecular physiology of reverse cholesterol transport." <i>J. Lipid Res.</i> 36: 211-228 | |
| | 40 | FIELDING et al. (1972) "A Protein of Lecithin: Cholesterol Acyltransferase." <i>Biochem. Biophys. Res. Comm.</i> 46(2):1493-1498 | |
| | 41 | FLEMING et al. (1999) "Clusterin is expressed in the anterior and intermediate lobes, but not in the posterior pituitary of sheep." <i>J Molecular Endocrinology</i> ; 23:199-208 | |
| | 42 | FRICKER et al. (1995) "Enteral Absorption of Octreotide: Modulation of Intestinal Permeability by Distinct Carbohydrates" <i>The Journal of Pharmacology and Experimental Therapeutics</i> 274:826-832 | |
| | 43 | FUESSL et al. (1987) "Oral Absorption of the Somatostatin Analogue SMS 201-995: Theoretical and Practical Implications" <i>Clinical Science</i> 72: 255-257. | |
| | 44 | GARBER et al. (1992) "Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties." <i>Arteriosclerosis and Thrombosis</i> , 12(8): 886-894 | |
| | 45 | GARBER et al. (1997) <i>Circulation</i> 96(8):I-490, Abstract 2744. | |
| | 46 | GARBER et al. (1999) <i>Circulation</i> 100(18):I-538, Abstract 2838. | |
| | 47 | GARBER et al. (2001) "A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis." <i>Journal of Lipid Research</i> 42:545-552 | |


| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CONFIDENTIAL

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

| | | |
|--|------------------------|----------------------------------|
| Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Complete if Known | |
| | Application Number | 10/120,508 10/520,207 |
| | Filing Date | April 5, 2002 |
| | First Named Inventor | Alan M. Fogelman |
| | Group Art Unit | 1654 |
| | Examiner Name | Jeffrey E. Russel |
| | Attorney Docket Number | 407T-301100US |
| Date Submitted | November 26, 2003 | |



| | | | |
|-----|----|---|--|
| JER | 48 | GELISSEN <i>et al.</i> (1998) "Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function?" <i>Biochem J</i> ; 331: 231-237 | |
| | 49 | GLOMSET (1968) "The Plasma lecithin: cholesterol acyltransferase reaction." <i>J. Lipid Res.</i> 9:155-167 | |
| | 50 | GONG <i>et al.</i> (1994) "Structural and functional properties of human and mouse apolipoprotein A-I." <i>Biochim. Biophys. Acta</i> 1213:335-342 | |
| | 51 | GRISWOLD (1987) "Biosynthesis and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells." <i>Biochemistry</i> ; 26:3297-3303 | |
| | 52 | GURFINKEL <i>et al.</i> (2002) "Influenza Vaccine Pilot Study in Acute Coronary Syndromes and Planned Percutaneous Coronary Interventions. The FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study" <i>Circulation</i> 105:2143-2147. | |
| | 53 | HAMASE <i>et al.</i> (2001) "Determination of Free D-Proline and D-Leucine in the Brains of Mutant Mice Lacking D-Amino Acid Oxidase Activity" <i>Analytical Biochemistry</i> 298:253-258. | |
| | 54 | HAMMAD <i>et al.</i> (1997) "Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide." <i>J Biol Chem</i> ; 272: 18644-18649 | |
| | 55 | HAN <i>et al.</i> (2001) "Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia." <i>Nature Medicine</i> ;7 338-343 | |
| | 56 | HARDY <i>et al.</i> (2001) "An Automated High-Performance Liquid Chromatography Procedure for the Quantitation of L- and D-Amino Acids by Means of Stepwise Precolumn Derivatization" <i>Analytical Biochemistry</i> 291:297-299. | |
| | 57 | HASAN <i>et al.</i> (2000) "Clusterin/apoJ expression during the development of hemangioma." <i>Hum Pathol</i> ; 31: 691-697 | |
| | 58 | HASHIMOTO <i>et al.</i> (2000) "Improvement of intestinal absorption of peptides: absorption of B1-Phe monoglucosylated insulin to rat intestinal brush-border membrane vesicles." <i>J. Pharmaceutics & Therapeutics</i> 50(2):197-204 | |
| | 59 | HAUSER <i>et al.</i> (1998) "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine" <i>Biochemistry</i> 178423-17850. | |
| | 60 | HAYRY <i>et al.</i> "Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat." <i>FASEB J.</i> 9(13):1336-1344 (1995) | |
| | 61 | HOCHGREBE <i>et al.</i> (1999) "A reexamination of the role of clusterin as a complement regulator." <i>Experimental Cell Research</i> ;249: 13-21 | |
| | 62 | HOUGH <i>et al.</i> (2001) "Coordinately up-regulated genes in ovarian cancer." <i>Cancer Res</i> ; 61: 3869-3876 | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CONFIDENTIAL

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

| | | |
|--|------------------------|----------------------------------|
| Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Complete if Known | |
| | Application Number | 10/420,500 10/520,207 |
| | Filing Date | April 5, 2002 |
| | First Named Inventor | Alan M. Fogelman |
| | Group Art Unit | 1654 |
| | Examiner Name | Jeffrey E. Russel |
| | Attorney Docket Number | 407T-301100US |
| | Date Submitted | November 26, 2003 |

| | | |
|-----|----|---|
| JER | 63 | HYKA et al. (2001) "Apolipoprotein A-I Inhibits the Production of Interleukin-1beta and Tumor Necrosis Factor-alpha by Blocking Contact-Mediated Activation of Monocytes by T Lymphocytes." <i>Blood</i> 97:2381-2389. |
| | 64 | ISHIKAWA et al. (1998) "Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta." <i>Arterioscler Thromb Vasc Biol</i> : 18: 665-672 |
| | 65 | ISHIKAWA et al. (2001) "Immunolocalization of apolipoproteins in aortic atherosclerosis in American youths and young adults: findings from the PDAY study." <i>Atherosclerosis</i> ; 158: 215-225 |
| | 66 | JENNE et al. (1989) "Molecular structure and functional characterization of a human complement cytotoxicity inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid." <i>Proc Natl Acad Sci USA</i> ; 86: 7123-7127 |
| | 67 | JOHNSON et al. (1991) "Cholesterol transport between cells and high-density lipoproteins." <i>Biochim. Biophys. Acta</i> . 1085: 273-298 |
| | 68 | JONAS (1991) "Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins." <i>Biochim. Biophys. Acta</i> 1084: 205-220 |
| | 69 | JONAS (2000) Lecithin cholesterol acyltransferase." <i>Biochim. Biophys. Acta</i> 1529: 245-256 |
| | 70 | JONES et al. (1992) "Computer Programs to Identify and Classify Amphipathic alpha Helical Domains" <i>Journal of Lipid Research</i> 33:287-296. |
| | 71 | KIGASAWA et al. (1995) "Inhibition of corneal ulceration by tetrapeptidyl hydroxamic acid." <i>Jap. J. Ophthalmology</i> 39(1):35-42 |
| | 72 | KISSINGER et al. (1982) "Analysis of Sertoli cell-secreted proteins by two-dimensional gel electrophoresis." <i>Biol Reprod</i> 1982; 27:233-240 |
| | 73 | KREIGER (1999) "Charting The Fate of the "Good Cholesterol": Identification and Characterization of the High-Density Lipoprotein Receptor Sr-Bi." <i>Ann Rev. Biochem.</i> 68: 523-558 |
| | 74 | KULLMAN et al. (1999) "Evaluation of the Enantiomeric Composition of Amino Acids in Tobacco" <i>Chirality</i> 11:669-673. |
| | 75 | LANDES (1995) Pp. 1-12 In: Clusterin: Role in Vertebrate Development, Function, and Adaptation (Harmony JAK Ed.) pp 1-12, R.G. |
| | 76 | LEVI et al. (2000) "A retro-inverso miniantibody with anti-HIV activity." <i>Aids Res. & Human Retrovirus</i> 16(1):59-65. |
| | 77 | LUNDIN et al. (1986) "Absorption of Intragastrically Administered DDAVP in Conscious Dogs" <i>Life Sciences</i> 38:703-709. |


| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CONFIDENTIAL

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

| | | |
|--|------------------------|----------------------------------|
| Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Complete if Known | |
| | Application Number | 10/120,508 10/520,207 |
| | Filing Date | April 5, 2002 |
| | First Named Inventor | Alan M. Fogelman |
| | Group Art Unit | 1654 |
| | Examiner Name | Jeffrey E. Russel |
| | Attorney Docket Number | 407T-301100US |
| | Date Submitted | November 26, 2003 |



| | | | |
|-----|----|---|--|
| JER | 78 | MACKNESS <i>et al.</i> (1997) "Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis." <i>Arterioscler Thromb Vasc Biol</i> ; 17: 1233-1238 | |
| | 79 | MACKNESS <i>et al.</i> (2001) "Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?" <i>Arterioscler Thromb Vasc Biol</i> ; 21:1451-1457 | |
| | 80 | MAN <i>et al.</i> (1987) "D-aspartate in human brain." <i>J Neurochem</i> 48:510-515 | |
| | 81 | MCLAUGHLIN <i>et al.</i> (2000) "Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis." <i>J Clin Invest</i> ; 106:1105-1113 | |
| | 82 | MERRIFIELD <i>et al.</i> (1995) "Retro and Retroenantio Analogs of Cecropin-Melittin Hybrids" <i>Proc Natl Acad Sci USA</i> 92: 3449-3453. | |
| | 83 | MISHRA <i>et al.</i> (1994) "Interactions of Synthetic Peptide Analogs of the Class A" <i>J. Biol. Chem.</i> 269: 7185-7191 | |
| | 84 | MISHRA <i>et al.</i> (1995) "Effect of the Arrangement of Tandem Repeating Units of Class A Amphipathic alpha-Helices on Lipid Interaction." <i>J. Biol. Chem.</i> 270: 1602-1611 | |
| | 85 | MISHRA <i>et al.</i> (1998) "Studies of Synthetic Peptides of Human Apolipoprotein A-I Containing Tandem Amphipathic alpha-Helices" <i>Biochemistry</i> 37: 10313-10324 | |
| | 86 | MITSUHASHI <i>et al.</i> (1997) "Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix." <i>J Clin Invest</i> ; 100: 847-854 | |
| | 87 | MOR <i>et al.</i> (1992) Enter a new post-translational modification: D-amino acids in gene-encoded peptides, <i>TIBS</i> , 17: 481-485 | |
| | 88 | MORRISSEY <i>et al.</i> (2001) "An antigen capture assay for the measurement of serum clusterin concentrations." <i>J Biochem Biophys Methods</i> ;48: 13-21 | |
| | 89 | NAGATA <i>et al.</i> (1994) "Distribution of free D-serine in vertebrate brains", <i>Brain Res.</i> , 634: 291-295. | |
| | 90 | NAGATA <i>et al.</i> (1995) "Free D-serine concentration in normal and Alzheimer human brain", <i>Brain Res. Bull.</i> , 38(2): 181-183 | |
| | 91 | NAVAB <i>et al.</i> (1997) "Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio." <i>J Clin Invest</i> ; 99:2005-2019 | |
| | 92 | NAVAB <i>et al.</i> (2000) "Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1." <i>J. Lipid Res.</i> 41: 1481-1494 | |
| | 93 | NAVAB <i>et al.</i> (2000) "Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3." <i>J. Lipid Res.</i> 41: 1495-1508 | |
| | 94 | NAVAB <i>et al.</i> (2001) "HDL and the inflammatory response induced by LDL-derived oxidized phospholipids." <i>Arterioscler Thromb Vasc Biol.</i> 21:481-488 | |


| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Copyright 1999

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

| | | |
|--|------------------------|----------------------------------|
| Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Complete if Known | |
| | Application Number | 10/120,500 10/520,207 |
| | Filing Date | April 5, 2002 |
| | First Named Inventor | Alan M. Fogelman |
| | Group Art Unit | 1654 |
| | Examiner Name | Jeffrey E. Russel |
| | Attorney Docket Number | 407T-301100US |
| | Date Submitted | November 26, 2003 |




| | | | |
|-----|-----|---|--|
| JER | 95 | NAVAB et al. (2002) "Oral Administration of an Apo A-I Mimetic Peptide Synthesized from D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol" <i>Circulation</i> 105: 290-292. | |
| | 96 | NEWKIRK et al. (1999) "Systemic lupus erythematosus, a disease associated with low levels of clusterin/apoJ, an anti-inflammatory protein." <i>J Rheumatol</i> ; 26: 597-603 | |
| | 97 | NISHIDA et al. (1999) "Apolipoproteins J and E co-localise with amyloid in gelatinous drop-like and lattice type I corneal dystrophies." <i>Br J Ophthalmol</i> ; 83: 1178-1182. | |
| | 98 | NOMOTO et al. (1998) "Improved of intestinal absorbtion of peptide drugs by Glycosylation: Transport of Tetrapeptide by the Sodium Ion-Dependent D-Glucose Transporter." <i>J. Pharmaceutics Science</i> 87(3):326-332. | |
| | 99 | OHTANI et al. (1995) Age-related changes in D-aspartic acid of rat teeth, <i>Growth Develop. & Aging</i> , 59: 55-61 | |
| | 100 | ORAM and YOKOYAMA (1996) "Apolipoprotein-mediated removal of cellular cholesterol and phospholipids." <i>J. Lipid Res.</i> 37: 2473-2491 | |
| | 101 | OWENS et al. (1990) "Apolipoprotein A-I and its Amphipathic Helix Peptide Analogues Inhibit Human Immunodeficiency Virus-Induced Syncytium Formation" <i>J Clin Invest</i> 86: 1142-1150. | |
| | 102 | PAIGEN et al. (1990) "Atherosclerosis Susceptibility Differences among Progenitors of Recombinant Inbred Strains of Mice." <i>Arteriosclerosis</i> 10: 316-323 | |
| | 103 | PALGUNACHARI et al. (1996) "Only the Two End Xelises of Eight Tandem Amphipathic Helical Domains of Human Apo A-I Have Significant Lipid Affinity." <i>Arteriosclerosis, Thrombosis, & Vascular Biology</i> 16: 328-338 | |
| | 104 | PANIZZUTTI et al. (2001) "A New Strategy to Decrease N-methyl-D-aspartate (NMDA) Receptor Coactivation: Inhibition of D-serine Synthesis by Converting Serine Racemase into an Eliminase" <i>PNAS</i> 98:5294-5299. | |
| | 105 | PAPPENHEIMER et al. (1994) "Intestinal Absorption and Excretion of Octapeptides Composed of D Amino Acids" <i>Proc Natl Acad Sci USA</i> 91: 1942-1945. | |
| | 106 | PAPPENHEIMER et al. (1997) "Absorption and Excretion of Undegradable Peptides: Roles of Lipid Solubility and Net Charge." <i>J. Pharmacology & Experimental Therapeutics</i> 280(1):292-300 | |
| | 107 | PATSZTY et al. (1994) "Apolipoprotein AI Transgene Corrects Apolipoprotein E Deficiency-induced Atherosclerosis in Mice." <i>J. Clinical Investigation</i> 94:899-903 | |
| | 108 | PENG et al. (2001) "Effects of L-glutamate, D-aspartate, and Monensin on Glycolytic and Oxidative Glucose Metabolism in Mouse Astrocyte Cultures: Further Evidence that Glutamate Uptake is Metabolically Driven by Oxidative Metabolism" <i>Neurochem. Int'l</i> 38:437-443. | |
| | 109 | PHARMALICENSING (27 Jan. 2001) Esperion Builds a Novel Peptides Program (2 pages) | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|--|------------------------|---------------------------------|
| Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Complete if Known | |
| | Application Number | 40420,508 10/520,207 |
| | Filing Date | April 5, 2002 |
| | First Named Inventor | Alan M. Fogelman |
| | Group Art Unit | 1654 |
| | Examiner Name | Jeffrey E. Russel |
| | Attorney Docket Number | 407T-301100US |
| | Date Submitted | November 26, 2003 |



| | | | |
|-----|-----|---|--|
| JER | 110 | PHARMALICENSING (28 Jan. 2001) Multiple Peptide Systems Forms Joint Venture With Elan | |
| | 111 | PHARMALICENSING (28 Jan. 2001) Unigene to Receive Patent for Delivery of Peptide Pharmaceuticals (2 pages) | |
| | 112 | PHILLIPS et al. (1993) "Plasma Lipoproteins and Progression of Coronary Artery Disease Evaluated by Angiography and Clinical Events." <i>Circulation</i> 88: 2762-2770 | |
| | 113 | PILONE (2000) D-amino acid oxidase: new findings. <i>CMLS, Cell. Mol. Life Sci.</i> , 57: 1732-1747 | |
| | 114 | PLUMP et al. (1994) "Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses stherosclerosis in the apolipoprotein E-deficient mouse." <i>Proc. Natl. Acad. Sci. USA</i> 91:9607-9611 | |
| | 115 | PURDUE NEWS (October 2000) 'Microspheres' Offer Promise for Oral Drug Delivery (3 pages) | |
| | 116 | PURDUE NEWS (September 12, 1997) New Oral Insulin Delivery System Shows Promise (3 pages) | |
| | 117 | REDONDO et al. (2000) "Overexpression of clusterin in human breast carcinoma." <i>Am J Pathol</i> ; 157:393-399 | |
| | 118 | REUBSAET et al. (1999) "Qualitative and quantitative aspects of the degradation of several tripeptides derived from the antitumour peptide antagonist [Arg ⁶ , D-Trp ^{7,9} , MePhe ⁸] substance P{6-11}." <i>J. Pharmaceut. & Biomed Analysis</i> 19(3-4):277-284 | |
| | 119 | RUBIN et al. (1991) "Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI." <i>Nature</i> 353:265-267 | |
| | 120 | SEGREST et al. (1974) "A Molecular Theory of Lipid-Protein Interaction in the Plasma Lipoproteins." <i>FEBS Lett.</i> 38: 247-253 | |
| | 121 | SEGREST et al. (1990) "Amphipathic Helix Motif: Classes and Properties." <i>Proteins: Structure, Function and Genetics</i> 8: 103-117 | |
| | 122 | SEGREST et al. (1991) Erratum <i>Proteins: Structure, Function and Genetics</i> 9:79 | |
| | 123 | SEGREST et al. (1992) "The Amphipathic Helix in the Exchangeable Apolipoproteins: A Review of Secondary Structure and Function" <i>J Lipid Research</i> 33:141-166. | |
| | 124 | SEGREST et al. (1994) "The Amphipathic alpha Helix: A Multifunctional Structural Motif in Plasma Apolipoproteins." <i>Adv. Prot. Chem.</i> 45: 303-369 | |
| | 125 | SEGREST et al. (2000) "Structure and function of apolipoprotein A-I and high-density lipoprotein." <i>Current Opin. Lipidol.</i> 11:105-115 | |
| | 126 | SENIOR (1999) "New options developed for needle-free drug delivery" <i>Lancet</i> Sept. 25, 1999 | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FILED

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

| | | |
|--|------------------------|----------------------------------|
| Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Complete if Known | |
| | Application Number | 10/120,508 10/520,207 |
| | Filing Date | April 5, 2002 |
| | First Named Inventor | Alan M. Fogelman |
| | Group Art Unit | 1654 |
| | Examiner Name | Jeffrey E. Russel |
| | Attorney Docket Number | 407T-301100US |
| | Date Submitted | November 26, 2003 |

| | | | |
|-----|-----|---|--|
| JER | 127 | SHAH et al. (1998) "Effect of Recombinant Apolipoprotein A-I _{Milano} on Aortic Atherosclerosis in Apolipoprotein E-Deficient Mice." <i>Circulation</i> 97:780-785. | |
| | 128 | SILKENSEN et al. (1999) "Identification of clusterin sequences mediating renal tubular cell interactions." <i>J. Pept Res</i> ; 54: 449-457 | |
| | 129 | SINGH et al. (2000) "Innate Defences Against Viraemia" <i>Rev Med Virol</i> 10:395-403. | |
| | 130 | SPRECHER et al. (1993) "The Low HDL Cholesterol/ High Triglyceride Trait." <i>Arterioscler. Thromb.</i> 13: 495-504 | |
| | 131 | SRINIVAS et al. (1990) "Antiviral Effects of Apolipoprotein A-I and Its Synthetic Amphipathic Peptide Analogs" <i>Virology</i> 176:48-57. | |
| | 132 | Starlix MC—Amino Acid Fact Sheet. http://www.starlix.com/media_center/content/pages/amino.htm . (12-10-2002) | |
| | 133 | STEINBERG et al. (1997) "Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer." <i>Clin Cancer Res</i> ;3: 1707-1711 | |
| | 134 | SU AND AMIDON (1995) Investigation into the intestinal metabolism of [D-Ala] peptide T amide: implication for oral drug delivery, <i>Biochim et Biophys.</i> , 1245: 62-68 | |
| | 135 | THE WALL STREET JOURNAL (Jan 13, 2000) "Emisphere technologies develops oral Heparin" | |
| | 136 | TSAI et al. (1998) D-serine added to antipsychotics for the treatment of schizophrenia. <i>Biol. Psychiatry</i> , 44: 1081-1089 | |
| | 137 | TSAO et al. (2001) "Hibernation-induction Peptide and Cell Death: [D-Ala ² , D-Leu ⁵]enkephalin Blocks Bax-related Apoptotic Processes" <i>European Journal of Pharmacology</i> 428:149-151. | |
| | 138 | TSIMIKAS et al. (2001) "Measuring Circulating Oxidized Low-Density Lipoprotein to Evaluate Coronary Risk." <i>Circulation</i> 103:1930-1932 | |
| | 139 | VAN LENTEN et al. (2001) "High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection." <i>Circulation</i> 103:2283-2288. | |
| | 140 | VAN LENTEN et al. (2001) "Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6." <i>J Biol Chem</i> ;276: 1923-1929 | |
| | 141 | VENKATACHALAPATHI et al. (1993) "Effect of End Group Blockage on the Properties of a Class A Amphipathic Helical Peptid." <i>Proteins:Structure, Function, and Genetics</i> 15:349-359 | |
| | 142 | WEHRLI et al. (2001) "Inhibition of post-ischemic brain injury by clusterin overexpression." <i>Nature Medicine</i> ; 7: 977-978 | |


| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CONFIDENTIAL

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

| | | |
|--|------------------------|----------------------------------|
| Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Complete if Known | |
| | Application Number | 10/120,508 10/520,207 |
| | Filing Date | April 5, 2002 |
| | First Named Inventor | Alan M. Fogelman |
| | Group Art Unit | 1654 |
| | Examiner Name | Jeffrey E. Russel |
| | Attorney Docket Number | 407T-301100US |
| | Date Submitted | November 26, 2003 |



| | | | |
|-----|-----|--|--|
| JER | 143 | WELLMANN <i>et al.</i> (2000) "Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas." <i>Blood</i> ; 96: 398-404 | |
| | 144 | WILSON <i>et al.</i> (1988) "High Density Lipoprotein Cholesterol and mortality: The Framingham Heart Study." <i>Arteriosclerosis</i> 8: 737-741 | |
| | 145 | WONG <i>et al.</i> (2000) "Clusterin protein diversity in the primate eye." <i>Mol. Vision</i> ; 6: 184-191 | |
| | 146 | XU <i>et al.</i> (2000) "Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle" <i>J Biol Chem</i> ; 275: 31770-3177 | |
| | 147 | YANCEY <i>et al.</i> (1995) "Efflux of Cellular Cholesterol and Phospholipid to Lipid-free Apolipoproteins and Class A Amphipathic Peptides." <i>Biochemistry</i> , 34: 7955-7965 | |
| | | | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Russel/ | Date Considered | 03/13/2007 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.